Product Description: Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor. Methyl brevifolincarboxylate has anti-oxidant activity. Methyl brevifolincarboxylate also inhibits platelet aggregation, lipid metabolism and inflammation[1][2][4][5][6].
Applications: COVID-19-anti-virus
Formula: C14H10O8
References: [1]Wu QY, et al. Chromatographic fingerprint and the simultaneous determination of five bioactive components of geranium carolinianum L. water extract by high performance liquid chromatography. Int J Mol Sci. 2011;12(12):8740-8749./[2]Fang SH, et al. Anti-oxidant and inflammatory mediator's growth inhibitory effects of compounds isolated from Phyllanthus urinaria. J Ethnopharmacol. 2008;116(2):333-340./[3]Iizuka T, et al. Vasorelaxant effects of methyl brevifolincarboxylate from the leaves of Phyllanthus niruri. Biol Pharm Bull. 2006 Jan;29(1):177-9. /[4]Iizuka T, et al. Inhibitory effects of methyl brevifolincarboxylate isolated from Phyllanthus niruri L. on platelet aggregation. Biol Pharm Bull. 2007 Feb;30(2):382-4.
CAS Number: 154702-76-8
Molecular Weight: 306.22
Research Area: Infection; Inflammation/Immunology; Cardiovascular Disease
Solubility: 10 mM in DMSO
Target: Influenza Virus